Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives
Open accessThe DOI matches its Crossref record; 98 of the 99 references it cites were found in a registry or an index.
Abstract
Benzodiazepines are some of the most commonly prescribed medications in the world. These sedative-hypnotics can provide rapid relief for symptoms like anxiety and insomnia, but are also linked to a variety of adverse effects (whether used long-term, short-term, or as needed). Many patients take benzodiazepines long-term without ever receiving evidence-based first-line treatments (e.g., psychotherapy, relaxation techniques, sleep hygiene education, serotonergic agents). This review discusses the risks and benefits of, and alternatives to benzodiazepines. We discuss evidence-based indications and contraindications, and the theoretical biopsychosocial bases for effectiveness, ineffectiveness and harm. Potential adverse effects and drug-drug interactions are summarized. Finally, both fast-acting/acute and delayed-action/chronic alternative treatments for anxiety and/or insomnia are discussed. Response to treatment—whether benzodiazepines, other pharmacological agents, or psychotherapy—should be determined based on functional recovery and not merely sedation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Benzodiazepines are commonly prescribed for anxiety and insomnia but are often misused for their sedative effects [64, 65].”
From Prevalence and patterns of substance use in West Africa: A systematic review and meta-analysis (2024) · cites this paper as [64]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Grant, B. F., Stinson, F. S., Dawson, D. A., Chou, S. P., Dufour, M. C., Compton, W., Pickering, R. P., & Kaplan, K. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.8.807 · Cited by 2,889
Neurobiologic advances from the brain disease model of addiction
Volkow, N. D., Koob, G. F., & McLellan, A. T. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1511480 · Cited by 2,008
Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults
Schutte-Rodin, S., Broch, L., Buysse, D., Dorsey, C., & Sateia, M. (2008) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27286 · Cited by 1,943 · cited 10×
“However, the study [21] acknowledged the difficulty prescribers face when they “inherit” patients who previously received BZDs from other prescribers (many of whom started BZDs prior to CPGs), creating “an immediate tension” as providers attempt to balance individual patient factors with the need to provide evidence-ba…”
BackgroundInfluentialSateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6470 · Cited by 1,519 · cited 9×
“However, the study [21] acknowledged the difficulty prescribers face when they “inherit” patients who previously received BZDs from other prescribers (many of whom started BZDs prior to CPGs), creating “an immediate tension” as providers attempt to balance individual patient factors with the need to provide evidence-ba…”
BackgroundInfluentialOpioid-induced Hyperalgesia: A Qualitative Systematic Review
Angst, M. S., & Clark, J. D. (2006) · Anesthesiology · doi:10.1097/00000542-200603000-00025 · Cited by 1,188
Substance Use Disorders in Patients With Posttraumatic Stress Disorder: A Review of the Literature
Jacobsen, L. K., Southwick, S. M., & Kosten, T. R. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1184 · Cited by 1,041 · cited 1×
“High rates of comorbidity suggest that PTSD and SUDs are functionally related, a concept supported by several studies indicating a pathway (likely related to corticotropin-releasing hormone and norepinephrine) whereby PTSD precedes substance use [69].”
BackgroundFava, M., Rush, A. J., Alpert, J. E., Balasubramani, G. K., Wisniewski, S. R., Carmin, C. N., Biggs, M. M., Zisook, S., Leuchter, A., Howland, R., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111868 · Cited by 927 · cited 1×
“These “antidepressants” (that are not only effective for depression) typically take four to six weeks before they exert clinical effect, though in the treatment of anxiety symptoms this delay can be even longer [30].”
BackgroundComparative Meta-Analysis of Pharmacotherapy and Behavior Therapy for Persistent Insomnia
Smith, M. T., Perlis, M. L., Park, A., Smith, M. S., Pennington, J., Giles, D. E., & Buysse, D. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.5 · Cited by 863 · cited 2×
“…SAD and insomnia, BZDs are frequently overprescribed for other indications for which there is no evidence of efficacy, to individuals who have contraindicated comorbid conditions, for longer periods of time than are recommended, and before other first and second-line treatments are tried [52–57].”
BackgroundBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Benzodiazepine Use in the United States
Olfson, M., King, M., & Schoenbaum, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1763 · Cited by 786
Posttraumatic stress disorder in general intensive care unit survivors: a systematic review
Davydow, D. S., Gifford, J. M., Desai, S. V., Needham, D. M., & Bienvenu, O. J. (2008) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2008.05.006 · Cited by 676
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617 · cited 1×
“, negative thoughts, insomnia, irritability, fatigue, suicidality) with depressive and anxiety disorders [19,35,38,66,78], a missed diagnosis of depression is possible when treating only anxiety or insomnia.”
BackgroundCognitive Effects of Long-Term Benzodiazepine Use: A Meta-Analysis
Barker, M. J., Greenwood, K. M., Jackson, M., & Crowe, S. F. (2004) · CNS Drugs · doi:10.2165/00023210-200418010-00004 · Cited by 552 · cited 3×
“Risk factors for BZD-induced neurocognitive disorder include older age (especially persistent use after 50 years old) [3,6,12,23], other substance use (especially alcohol), other NCDs (especially TBI), delirium (in which even very low doses of BZDs may be intoxicating), longer use and primary psychiatric disorders (es…”
BackgroundOpioid-induced abnormal pain sensitivity: implications in clinical opioid therapy
Mao, J. (2002) · Pain · doi:10.1016/s0304-3959(02)00422-0 · Cited by 462 · cited 1×
“, opioid-induced hyperalgesia, in which chronic opioid use makes patients more sensitive to pain) [101,102].”
BackgroundThe diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455 · cited 15×
“Benzodiazepines (BZDs) are some of the most commonly prescribed medications in the world [1,2].”
BackgroundInfluentialBremner, J. D., Innis, R. B., Southwick, S. M., Staib, L., Zoghbi, S., & Charney, D. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.7.1120 · Cited by 453
Addiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives.
Longo, L. P., & Johnson, B. (2000) · PubMed · Cited by 420
Prolonged exposure in patients with chronic PTSD: predictors of treatment outcome and dropout
van Minnen, A., Arntz, A., & Keijsers, G. P. J. (2002) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(01)00024-9 · Cited by 393 · cited 1×
“…baseline) [1,8]; BZDs increasing fear responses after stressful exposures likely by fear-sensitization and generalizing conditioneddefeat [60,61,103,104]; BZDs being associated with a loss of self-confidence in one’s ability to cope with stressors without medications [83]; and BZDs indirectly…”
BackgroundAnxiety, anxiety disorders, tobacco use, and nicotine: A critical review of interrelationships.
Morissette, S. B., Tull, M. T., Gulliver, S. B., Kamholz, B. W., & Zimering, R. T. (2007) · Psychological Bulletin · doi:10.1037/0033-2909.133.2.245 · Cited by 380 · cited 1×
“Similar concepts have been studied with nicotine (which is associated with worse anxiety with chronic use and improvement after discontinuation) [99,100] and opioids (i.”
BackgroundBallenger, J. C., Davidson, J. R., Lecrubier, Y., Nutt, D., Foa, E. B., Kessler, R. C., McFARLANE, A. C., & Shalev, A. Y. (2000) · PubMed · Cited by 375
Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: A systematic review
Berger, W., Mendlowicz, M. V., Marques-Portella, C., Kinrys, G., Fontenelle, L. F., Marmar, C. R., & Figueira, I. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.12.004 · Cited by 347 · cited 3×
“However, because not all individuals respond or fully remit, or have adverse effects with these treatments, it is important to know options for those who have continuing symptoms or do not tolerate first-line treatments [45].”
BackgroundInfluentialBenzodiazepines for PTSD: A Systematic Review and Meta-Analysis
GUINA, J., ROSSETTER, S. R., DeRHODES, B. J., NAHHAS, R. W., & WELTON, R. S. (2015) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000091 · Cited by 341 · cited 7×
“To the contrary, PTSD [31,36,44,58] and phobias [59] have evidence of ineffectiveness or even harm.”
BackgroundInfluentialSelf-citationTreatment of recent trauma survivors with benzodiazepines: a prospective study.
Gelpin, E., Bonne, O. B., Peri, T., Brandes, D., & Shalev, A. Y. (1996) · PubMed · Cited by 322
The effects of benzodiazepine use during pregnancy and lactation
McElhatton, P. R. (1994) · Reproductive Toxicology · doi:10.1016/0890-6238(94)90029-9 · Cited by 265 · cited 1×
“Early evidence suggested a heightened risk of facial anomalies though this finding has not been consistently found and may have been confounded by other predisposing teratogenic etiologies (e.g., anti-epileptic drugs) [92].”
BackgroundGriffiths, R. R., & Weerts, E. M. (1997) · Psychopharmacology · doi:10.1007/s002130050422 · Cited by 260 · cited 16×
“High rates of comorbidity suggest that PTSD and SUDs are functionally related, a concept supported by several studies indicating a pathway (likely related to corticotropin-releasing hormone and norepinephrine) whereby PTSD precedes substance use [69].”
BackgroundInfluentialConceptually Driven Pharmacologic Approaches to Acute Trauma
Pitman, R. K., & Delahanty, D. L. (2005) · CNS Spectrums · doi:10.1017/s109285290001943x · Cited by 250 · cited 1×
“However, global CNS inhibition also leads to adverse effects via every area of the brain including motor, sensory, speech, and respiratory impairments [19,58,74,85].”
BackgroundBasic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal
Bateson, A. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023396681 · Cited by 240 · cited 2×
“Tolerance develops to hypnotic effects within days to weeks, to myorelaxant effects within weeks, to anticonvulsant effects within weeks to months, and to anxiolytic effects within months [1,8,83,96].”
BackgroundGray, S. L., Dublin, S., Yu, O., Walker, R., Anderson, M., Hubbard, R. A., Crane, P. K., & Larson, E. B. (2016) · BMJ · doi:10.1136/bmj.i90 · Cited by 233 · cited 1×
“In fact, BZDs can cause dementia which persists after discontinuation of use [3,98].”
Background(2015) · PubMed · Cited by 229
Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified?
Lader, M. H. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)00051-6 · Cited by 220 · cited 8×
““The risk/benefit ratio of these drugs becomes less favorable or even adverse as treatment becomes prolonged: Efficacy wanes and risks accumulate” [15].”
BackgroundInfluentialTraumatic brain injury, posttraumatic stress disorder, and pain diagnoses in OIF/OEF/OND veterans
Cifu, D. X., Taylor, B. C., Carne, W. F., Bidelspach, D., Sayer, N. A., Scholten, J., & Campbell, E. H. (2013) · Journal of Rehabilitation Research and Development · doi:10.1682/jrrd.2013.01.0006 · Cited by 219 · cited 1×
“[3,76].”
Manual of Clinical Psychopharmacology
Schatzberg, A. F., & DeBattista, C. (2015) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615370047 · Cited by 202
Reduced GABAA benzodiazepine receptor binding in veterans with post-traumatic stress disorder
Geuze, E., van Berckel, B. N. M., Lammertsma, A. A., Boellaard, R., de Kloet, C. S., Vermetten, E., & Westenberg, H. G. M. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002054 · Cited by 198 · cited 1×
“Some have postulated that underlying differences in GABA receptors can predispose individuals to develop anxiety disorders, and/or that trauma/stressors can induce modulation or downregulation of GABA receptors in those that develop anxiety disorders [48].”
BackgroundCURRAN, H. V., COLLINS, R., FLETCHER, S., KEE, S. C. Y., WOODS, B., & ILIFFE, S. (2003) · Psychological Medicine · doi:10.1017/s0033291703008213 · Cited by 190 · cited 10×
“, distribution, metabolism, elimination), increased use of additional medications that can compound adverse effects, and increased presence of even minimal brain damage [8,13,73].”
BackgroundInfluentialSSRIs versus Non-SSRIs in Post-traumatic Stress Disorder: An Update with Recommendations
Asnis, G. M., Kohn, S. R., Henderson, M., & Brown, N. L. (2004) · Drugs · doi:10.2165/00003495-200464040-00004 · Cited by 181
Offidani, E., Guidi, J., Tomba, E., & Fava, G. A. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000353198 · Cited by 166
What Happens to Anxiety Levels on Giving Up Smoking?
West, R., & Hajek, P. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.11.1589 · Cited by 161 · cited 1×
“Similar concepts have been studied with nicotine (which is associated with worse anxiety with chronic use and improvement after discontinuation) [99,100] and opioids (i.”
BackgroundNeuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence
Allison, C., & Pratt, J. A. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(03)00029-9 · Cited by 160 · cited 2×
“Chronic BZD-induced enhancement of GABA also likely results in a compensatory sensitization of excitatory systems (including glutamate) [1,97].”
BackgroundBenzodiazepine withdrawal: outcome in 50 patients
ASHTON, H. (1987) · British Journal of Addiction · doi:10.1111/j.1360-0443.1987.tb01529.x · Cited by 160 · cited 2×
“This explains why patients commonly increase dosage over time and many eventually take more than one type of BZD after the first loses effectiveness [1,3,4,73,79].”
BackgroundComorbid anxiety as a suicide risk factor among depressed veterans
Pfeiffer, P. N., Ganoczy, D., Ilgen, M., Zivin, K., & Valenstein, M. (2009) · Depression and Anxiety · doi:10.1002/da.20583 · Cited by 153 · cited 2×
“Risk factors for attempted and completed suicide while using BZDs include BZD intoxication, repeated BZD intoxication, high doses of prescribed BZDs, and underlying depression [3,23,82].”
BackgroundPharmacotherapy of PTSD: premises, principles, and priorities.
Ravindran, L. N., & Stein, M. B. (2009) · Brain Research · doi:10.1016/j.brainres.2009.03.037 · Cited by 153 · cited 3×
“However, global CNS inhibition also leads to adverse effects via every area of the brain including motor, sensory, speech, and respiratory impairments [19,58,74,85].”
BackgroundAnxiety disorders: a comprehensive review of pharmacotherapies
Hoffman, E. J., & Mathew, S. J. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20041 · Cited by 149
Use of antianxiety agents in anxious outpatients
Rickels, K. (1978) · Psychopharmacology · doi:10.1007/bf00426784 · Cited by 141 · cited 2×
“do not, at least in a direct sense, affect the characterologic or personality side of the patient,” many were excited about the hope that they could “facilitate problem solving, contribute to the de- and reconditioning of emotional responses, and enable the patient to cope with intra- and extrapsychic stress more appr…”
BackgroundMichelini, S., Cassano, G., Frare, F., & Perugi, G. (2007) · Pharmacopsychiatry · doi:10.1055/s-2007-979558 · Cited by 135 · cited 10×
“, distribution, metabolism, elimination), increased use of additional medications that can compound adverse effects, and increased presence of even minimal brain damage [8,13,73].”
BackgroundInfluentialMohamed, S., & Rosenheck, R. A. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0611 · Cited by 115
New insights into secondary prevention in post-traumatic stress disorder
Zohar, J., Juven-Wetzler, A., Sonnino, R., Cwikel-Hamzany, S., Balaban, E., & Cohen, H. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.2/jzohar · Cited by 112 · cited 1×
“…various conditions: Anxiety, insomnia, substance withdrawal, anesthesia, muscle tension, seizures, psychosis, depression, narcosynthesis (aka the “BZD interview”) for combat neurosis, ordinary life stressors, vague psychosomatic complaints, and even arrhythmias and myocardial infarction [1,5–9].”
Bushnell, G. A., Stürmer, T., Gaynes, B. N., Pate, V., & Miller, M. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1273 · Cited by 109
Combination Treatment With Benzodiazepines and SSRIs for Comorbid Anxiety and Depression: A Review
Dunlop, B. W., & Davis, P. G. (2008) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v10n0307 · Cited by 106
Cates, M. E., Bishop, M. H., Davis, L. L., Lowe, J. S., & Woolley, T. W. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1e043 · Cited by 105 · cited 1×
“Table 2 attempts to summarize an exhaustive list of cognitive, emotional, behavioral, perceptual and physical adverse effects from BZDs [1,3,4,8,11,15,24,31,59,74,78–80,83 ,87 Extra caution is recommended when prescribing BZDs to the elderly.”
BackgroundThe APA Task Force report on benzodiazepine dependence, toxicity, and abuse
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.2.151 · Cited by 101 · cited 6×
“BZD toxicity in the elderly can cause cognitive impairment even with short-term therapeutic doses [11].”
BackgroundInfluentialBenzodiazepines versus placebo for panic disorder in adults
Breilmann, J., Girlanda, F., Guaiana, G., Barbui, C., Cipriani, A., Castellazzi, M., Bighelli, I., Davies, S. J., Furukawa, T. A., & Koesters, M. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010677.pub2 · Cited by 98
Pharmacotherapy for posttraumatic stress disorder: Review with clinical applications
Jeffreys, M., Capehart, B., & Friedman, M. J. (2012) · The Journal of Rehabilitation Research and Development · doi:10.1682/jrrd.2011.09.0183 · Cited by 98 · cited 6×
“BZDs have demonstrated the ability to interfere with fear extinction [17,23,39], which is critical for the improvement of anxiety and is likely why BZDs have been found to increase fear conditioning with phobias [59] and to have fear-sensitizing effects in response tostress [23,60,61].”
BackgroundInfluentialChronic benzodiazepine usage and withdrawal in insomnia patients
Poyares, D., Guilleminault, C., Ohayon, M. M., & Tufik, S. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2003.10.003 · Cited by 94 · cited 4×
“Several studies have demonstrated that even short-term BZD use can worsen several sleep parameters: Decreasing sleep time, increasing rapid eye movement (REM) sleep latency, decreasing slow wave sleep (stages 3 and 4 non-REM sleep), increasing stage 2 non-REM sleep and decreasing delta count [1,12,72,73].”
BackgroundInfluentialDavidson, J. R. T. (2004) · The Journal of Clinical Psychiatry · Cited by 91
Recent developments in the psychopharmacology of anxiety disorders.
Lydiard, R. B., Brawman-Mintzer, O., & Ballenger, J. C. (1996) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.64.4.660 · Cited by 91
Morin, C. M., Bélanger, L., Bastien, C., & Vallières, A. (2005) · Behaviour Research and Therapy · doi:10.1016/j.brat.2003.12.002 · Cited by 91 · cited 5×
“, distribution, metabolism, elimination), increased use of additional medications that can compound adverse effects, and increased presence of even minimal brain damage [8,13,73].”
BackgroundInfluentialLong-term use of benzodiazepines and nonbenzodiazepine hypnotics, 1999-2014.
Kaufmann, C. N., Spira, A. P., Depp, C. A., & Mojtabai, R. (2018) · Psychiatric Services · doi:10.1176/appi.ps.201700095 · Cited by 85 · cited 1×
“Total BZD use actually increased from 1999 to 2014, largely driven by increases in long-term use [16].”
Background(2008) · Wiley eBooks · doi:10.1002/9780470515167 · Cited by 84
Acute and delayed effects of alprazolam on flight phobics during exposure
Wilhelm, F. H., & Roth, W. T. (1997) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(97)00033-8 · Cited by 82
Matar, M. A., Zohar, J., Kaplan, Z., & Cohen, H. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.12.004 · Cited by 77 · cited 2×
“BZDs have demonstrated the ability to interfere with fear extinction [17,23,39], which is critical for the improvement of anxiety and is likely why BZDs have been found to increase fear conditioning with phobias [59] and to have fear-sensitizing effects in response tostress [23,60,61].”
BackgroundPilot evaluation of hypnotic medication during acute traumatic stress response
Mellman, T. A., Byers, P. M., & Augenstein, J. S. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024460814230 · Cited by 77 · cited 1×
“Insomnia is one of the most common chief complaints of patients with mental disorders, and sleep deprivation can cause fatigue, irritability, inattention, depression, anxiety, dysfunction, and reduced quality of life [21,63,73].”
BackgroundHeather, N., Bowie, A., Ashton, H., McAvoy, B., Spencer, I., Brodie, J., & Giddings, D. (2004) · Addiction Research & Theory · doi:10.1080/1606635310001634528 · Cited by 77 · cited 2×
“, falls, fights, motor vehiclecollisions) [1,3,11,13,23,31,71,105].”
BackgroundDeclining Benzodiazepine Use in Veterans With Posttraumatic Stress Disorder
Lund, B. C., Alexander, B., Bernardy, N. C., & Friedman, M. J. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06775 · Cited by 74 · cited 5×
“VA Researchers [14] speculated that “ideally, benzodiazepine use has decreased because veterans with Posttraumatic stress disorder (PTSD) are receiving higher rates of evidence-based treatments for core symptoms, including cognitive-behavioral therapy and adequate trials of first-line medications, thereby minimizing re…”
BackgroundInfluentialRisse, S. C., Whitters, A. C., Burke, J., Chen, S., Scurfield, R. M., & Raskind, M. A. (1990) · PubMed · Cited by 72
The effects of chronic valproate and diazepam in a mouse model of posttraumatic stress disorder
Li, S., MURAKAMI, Y., Wang, M., Maeda, K., & Matsumoto, K. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.08.015 · Cited by 69
The American Psychiatric Association Publishing Textbook of Psychopharmacology
Schatzberg, A., & Nemeroff, C. (2017) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615371624 · Cited by 69
Central type benzodiazepine receptors in Gulf War veterans with posttraumatic stress disorder
Fujita, M., Southwick, S. M., DeNucci, C. C., Zoghbi, S. S., Dillon, M. S., Baldwin, R. M., Bozkurt, A., Kugaya, A., Verhoeff, N. P. L. G., Seibyl, J. P., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.03.010 · Cited by 65 · cited 1×
“…to correlate with common anxiety symptoms: Amygdala (emotional modulation dysfunction and fear conditioning), prefrontal cortex (attention and working memory deficits), hippocampus (memory formation dysfunction), and striatum (salience reactivity and misinterpretation of aversivestimuli) [48–50].”
BackgroundPrescribing Trends in Veterans With Posttraumatic Stress Disorder
Bernardy, N. C., Lund, B. C., Alexander, B., & Friedman, M. J. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07311 · Cited by 64 · cited 2×
“Meanwhile, decreased BZD prescription for PTSD patients correlates with increased prescription of antidepressants [24,27], trazodone [17], prazosin, quetiapine, and non-BZD hypnotics [27].”
BackgroundPrescribing Trends in Veterans With Posttraumatic Stress Disorder
Talbott, J. A. (2012) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/j.ypsy.2012.07.122 · Cited by 58
Antidepressants and benzodiazepines for panic disorder in adults
Bighelli, I., Trespidi, C., Castellazzi, M., Cipriani, A., Furukawa, T. A., Girlanda, F., Guaiana, G., Koesters, M., & Barbui, C. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011567.pub2 · Cited by 57 · cited 1×
“While serotonergic agents have stronger efficacy for anxiety than BZDs, it is notable that a 2016 Cochrane review [56] concluded insufficient evidence exists to compare antidepressants to BZDs for the treatment of PD in terms of efficacy and tolerability.”
BackgroundPharmacologic Treatment of Posttraumatic Stress Disorder Among Privately Insured Americans
Harpaz-Rotem, I., Rosenheck, R. A., Mohamed, S., & Desai, R. A. (2008) · Psychiatric Services · doi:10.1176/ps.2008.59.10.1184 · Cited by 51 · cited 5×
“Unfortunately, some of these factors—particularly SUDs and borderline personality disorder—also correlate with increased BZD prescriptions [20,22,23,25,26].”
BackgroundResultInfluentialHawkins, E. J., Malte, C. A., Imel, Z. E., Saxon, A. J., & Kivlahan, D. R. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.01.003 · Cited by 49
Benzodiazepine Use in Posttraumatic Stress Disorder among Veterans with Substance Abuse
KOSTEN, T. R., FONTANA, A., SERNYAK, M. J., & ROSENHECK, R. (2000) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-200007000-00010 · Cited by 45
Do Benzodiazepines Reduce the Effectiveness of Exposure Therapy for Posttraumatic Stress Disorder?
Rosen, C. S., Greenbaum, M. A., Schnurr, P. P., Holmes, T. H., Brennan, P. L., & Friedman, M. J. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08592 · Cited by 44 · cited 1×
“…are contraindicated for BZDs (e.g., SUD, traumatic brain injury [TBI], depression); and BZDs can inhibit trauma-focused psychotherapy by promoting avoidance of exposure, numbing trauma-related emotions, and inhibiting of cognitive processing (all of which is necessary for recovery) [3,58,62–65].”
BackgroundAligning Clinical Practice to PTSD Treatment Guidelines: Medication Prescribing by Provider Type
Abrams, T. E., Lund, B. C., Bernardy, N. C., & Friedman, M. J. (2013) · Psychiatric Services · doi:10.1176/appi.ps.201200217 · Cited by 42 · cited 3×
“Insomnia is one of the most common chief complaints of patients with mental disorders, and sleep deprivation can cause fatigue, irritability, inattention, depression, anxiety, dysfunction, and reduced quality of life [21,63,73].”
BackgroundResultWikner, B. N., Stiller, C., Källén, B., & Asker, C. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1391 · Cited by 38
Benzodiazepines - Their role in aggression and why GPs should prescribe with caution.
Jones, K. A., Nielsen, S., Bruno, R., Frei, M. Y., & Lubman, D. I. (2011) · PubMed · Cited by 38
Clonazepam‐related sexual dysfunction in male veterans with PTSD
Fossey, M. D., & Hamner, M. B. (1994) · Anxiety · doi:10.1002/anxi.3070010508 · Cited by 38 · cited 1×
“, negative thoughts, insomnia, irritability, fatigue, suicidality) with depressive and anxiety disorders [19,35,38,66,78], a missed diagnosis of depression is possible when treating only anxiety or insomnia.”
BackgroundConcomitant prescribing of benzodiazepines during antidepressant therapy in the elderly
van Dijk, K. N., de Vries, C. S., Huurne, K. K.-T., van den Berg, P. B., Brouwers, J. R. B. J., & den Berg, L. T. W. D. J. (2002) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(02)00457-2 · Cited by 36 · cited 1×
“Unfortunately, there is no evidence to support this practice, the combination may increase adverse effects without increasing therapeutic effects, and it is not uncommon for patients to continue BZDs long-term in the presence or absence of the antidepressant [2,34].”
BackgroundPharmacotherapy of anxious disorders
Bourin, M., & Lambert, O. (2002) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.435 · Cited by 36 · cited 2×
“Some argue to “limit benzodiazepine prescriptions to emergency situations where a rapid symptomatic amelioration is required before the onset of action of antidepressant treatment allows the reduction and finally the cessation of benzodiazepines” [35].”
BackgroundLund, B. C., Bernardy, N. C., Vaughan-Sarrazin, M., Alexander, B., & Friedman, M. J. (2013) · Psychiatric Services · doi:10.1176/appi.ps.201200267 · Cited by 32 · cited 14×
“For example, as many as 94% of PTSD patients using BZDs receive at least 30 day supplies and about two-thirds receive at least 90 day supplies [14,17].”
BackgroundInfluentialLongitudinal Correlates of Aggressive Behavior in Help‐Seeking U.S. Veterans With PTSD
Shin, H. J., Rosen, C. S., Greenbaum, M. A., & Jain, S. (2012) · Journal of Traumatic Stress · doi:10.1002/jts.21761 · Cited by 28 · cited 2×
“Risk factors for paradoxical reactions with BZDs include other substance use (especially alcohol) [24,90,105], neurocognitive disorders (especially TBI) [17,84,105], a history of disinhibition or impulsivity (especially with borderline personality disorder) [39,105,106], anxiety disorders [24,90], older age [31], lear…”
BackgroundMorgan, M., Lockwood, A., Steinke, D. T., Schleenbaker, R. E., & Botts, S. R. (2012) · Psychiatric Services · doi:10.1176/appi.ps.201000531 · Cited by 27 · cited 2×
“Even more concerning, several studies have demonstrated high rates of sedative-hypnotics among patients with contraindicated comorbid psychiatric disorders: Depressive, substance use [20,22] and neurocognitive disorders [20,22,77].”
BackgroundResultHermos, J. A., Young, M., Lawler, E. V., Rosenbloom, D., & Fiore, L. D. (2007) · Journal of Traumatic Stress · doi:10.1002/jts.20254 · Cited by 25 · cited 7×
“…[17,20,22–25], substance use disorders (SUDs) [20,22,23,26], inpatient psychiatric treatment [20,24], longer duration of disorder [14,17], more VA disability compensation [17,20], concurrent opioid prescriptions [23,26], concurrent prescriptions for other BZDs [26], and number of traumas [25].”
BackgroundInfluentialDiazepam enhances conditioned defeat in hamsters (Mesocricetus auratus)
Hebert, M. A., Potegal, M., Moore, T. O., Evenson, A. R., & Meyerhoff, J. L. (1996) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00110-4 · Cited by 24
Antidepressants and benzodiazepines for panic disorder in adults
Guaiana, G., Barbui, C., Bighelli, I., Trespidi, C., Chiodo, D., Cipriani, A., Davies, S., & Koesters, M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011567 · Cited by 23
Holbrook, A. M. (2004) · BMJ · doi:10.1136/bmj.329.7476.1198 · Cited by 21
Pharmacological treatment of combatinduced PTSD: a literature review
Lynn, D. (2010) · British Journal of Nursing · doi:10.12968/bjon.2010.19.5.47074 · Cited by 19
Saleh, F. M., Fedoroff, J. P., Ahmed, A. G., & Pinals, D. A. (2008) · doi:10.1002/9780470515167.ch127 · Cited by 16
Substance Abuse: Sedative, Hypnotic, or Anxiolytic Use Disorders
Wesson, D. R., Smith, D. E., Ling, W. W., & Sabnani, S. (2008) · Wiley eBooks · doi:10.1002/9780470515167.ch64 · Cited by 12
Benzodiazepine Exposure and History of Trauma
Sansone, R. A., Hruschka, J., Vasudevan, A. R., & Miller, S. N. (2003) · Psychosomatics · doi:10.1176/appi.psy.44.6.523 · Cited by 12 · cited 3×
“Unfortunately, some of these factors—particularly SUDs and borderline personality disorder—also correlate with increased BZD prescriptions [20,22,23,25,26].”
BackgroundA Pharmacotherapeutic Approach to the Management of Chronic Posttraumatic Stress Disorder
Spaulding, A. M. (2012) · Journal of Pharmacy Practice · doi:10.1177/0897190012442714 · Cited by 11 · cited 1×
“, negative thoughts, insomnia, irritability, fatigue, suicidality) with depressive and anxiety disorders [19,35,38,66,78], a missed diagnosis of depression is possible when treating only anxiety or insomnia.”
BackgroundMotivational drive and alprazolam misuse: A recipe for aggression?
Albrecht, B., Staiger, P. K., Hall, K., Kambouropoulos, N., & Best, D. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.04.040 · Cited by 10 · cited 1×
“Risk factors for paradoxical reactions with BZDs include other substance use (especially alcohol) [24,90,105], neurocognitive disorders (especially TBI) [17,84,105], a history of disinhibition or impulsivity (especially with borderline personality disorder) [39,105,106], anxiety disorders [24,90], older age [31], lear…”
BackgroundBostwick, J. R., Casher, M. I., & Yasugi, S. (2012) · Current psychiatry · Cited by 6
Pharmacological Treatment of Substance Abuse Disorders
Raby, W. N., Mariani, J. J., LEVIN, F. R., & Nunes, E. V. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch113 · Cited by 4
Pharmacological Treatment of Substance Abuse Disorders
Raby, W. N., LEVIN, F. R., & Nunes, E. V. (2008) · doi:10.1002/9780470515167.ch111 · Cited by 3
Psychiatric Conditions in Women during Reproductive Transitions
Kim, H. G., Raymond, N. C., & Kornstein, S. G. (2008) · doi:10.1002/9780470515167.ch119 · Cited by 1
Research works printed but not linked: 6
- Pary, 2008, Prescribing benzodiazepines in clinical practice, Resid. Staff Phys., 54, 8
- Stahl, S.M. (2013). Essential Psychopharmacology, Cambridge. [4th ed.].
- Powers, M., Becker, E., Gorman, J., Kissen, D., Smits, J., and Anxiety and Depression Association of America (2017, October 20). Clinical Practice Review for GAD. Available online: https:/adaa.org.
- Foa, E.B., Keane, T.M., Friedman, M.J., and Cohen, J.A. (2009). Effective Treatments for PTSD: Practice Guidelines from the International Society for Traumatic Stress Studies, Guilford Press. [2nd ed.].
- Ader, R. (2006). Psychoneuroimmunology, Elsevier Academic Press.
- Tasman, 2008, Pharmacological issues during pregnancy, Psychiatry, Volume 1, 2423
Cited by
Sartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
Targeting synapse function and loss for treatment of neurodegenerative diseases
Dejanovic, B., Sheng, M., & Hanson, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00823-1 · Cited by 193
“GABAAR PAMs including benzodiazepines are used for treating epilepsy and forms of anxiety disorder 192 .”
Sumsuzzman, D. M., Choi, J., Jin, Y., & Hong, Y. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.04.034 · Cited by 123
Massoudi, B., Holvast, F., Bockting, C. L. H., Burger, H., & Blanker, M. H. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.11.050 · Cited by 101
Detyniecki, K., Van Ess, P. J., Sequeira, D. J., Wheless, J. W., Meng, T., & Pullman, W. E. (2019) · Epilepsia · doi:10.1111/epi.15159 · Cited by 105
Metadata
- Authors
- Guina, J., & Merrill, B.
- Affiliations
- Wright State University (US)
- Corresponding author
- Guina, Jeffrey
- ORCID
- Guina, Jeffrey
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2018-01-30
- Volume
- 7
- Issue
- 2
- Pages
- 17
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC5852433
- OpenAlex
- W2793017265
- Semantic Scholar
- 81e4137cd04cbc40756500350418397c8843db63
- Cited by
- 253
- References
- 99
- Citations by year
- 2026: 15 · 2025: 23 · 2024: 34 · 2023: 42 · 2022: 32 · 2021: 42 · 2020: 34 · 2019: 25 · 2018: 6
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Journal of Bioresource Management (submittedVersion, cc-by)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- benzodiazepines, sedative-hypnotic drugs, anxiety, insomnia, adverse effects, drug-drug interactions, long-term benzodiazepine use, psychotherapy, sleep hygiene, serotonergic agents, functional recovery, biopsychosocial model
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.